Health News Releases

  • Today August 23
August 22, 09:35
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54311084&newsitemid=20250821182068&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
August 13, 10:10
PL Developments Builds a Smarter, Healthier Supply Chain with Kinaxis
Kinaxis® (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54306533&newsitemid=20250812652131&lan=en-US&anchor=Kinaxis%26%23174%3B&index=1&md5=43390a81b573
August 08, 17:10
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosi
August 08, 15:00
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter o
HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics
August 08, 11:20
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.histosonics.com&esheet=54304409&newsitemid=20250807749442&lan=en-US&anchor=HistoSonics&index=1&md5=f0e9f5c34e97c8b8bfd
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study
August 05, 15:50
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
Concept Medical Inc. (https://www.conceptmedical.com/), a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Ba
August 05, 15:00
Nucleus Network Acquires Hammersmith Medicines Research
Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom’s most respected early phase clini
August 01, 13:40
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54299902&newsitemid=20250731014937&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
July 30, 16:11
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54297300&newsitemid=20250727920112&lan=en-US&anc
XTRAIA XD-3300
July 30, 15:40
Rigaku Launches XTRAIA XD-3300 Mass Production for Semiconductor Market
Rigaku Corporation, a global solution partner in X-ray metrology systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), ha
Novotech Veeva Hero Award 2025 Recipient
July 30, 15:20
Novotech Awarded Veeva Hero Award at 2025 Veeva R&D and Quality Summit
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Q
BARRICURE booth at SPDU 2025, Imperial Hotel Kuching, Malaysia
July 29, 11:54
BARRICURE Officially Sponsors SPDU 2025 in Malaysia Collaborating with CHAYA AND LIGHT SDN. BHD. for Local Professional Promotion
BARRICURE, the dermatology-focused medical device brand of MEDIPEAU Inc, Ltd., participated as an official sponsor at the Sarawak Paediatric Dermatology Update 2025 (SPDU 2025), held on July 26, 2025,
July 29, 11:10
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54297275&newsitemid=20250728331235&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
July 29, 10:55
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technolo
Software image
July 27, 10:33
Endoscopic AI: AI Medical Service Inc. Has Obtained Regulatory Approval from Thailand’s FDA for Its Gastric AI-based Endoscopic Diagnosis Support System
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce that it has received medical device approval from the
Amazfit Announces Ultra Runner Rod Farvard as New Brand Ambassador
July 25, 13:30
Amazfit Announces Ultra Runner Rod Farvard as New Brand Ambassador
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced ultra runner Rod Farvard as the newest athlete ambassador. Farvard’s approach to endurance racing, a combin
July 25, 11:30
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of m
July 24, 14:52
Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025. · Record net sales of 2.448 billion USD, representing net
July 23, 14:30
Takeda Receives FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices to Simplify HYQVIA® Administration
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub™ and HyHub™ Duo, devices
July 22, 14:05
SS&C Technologies to Acquire Calastone
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2025-Enterprise-Press-Release-0725&utm_medium=pressrelease&utm_source=prnews&utm_content=SSNC-to-acquire-Calastone) (Nasdaq:
July 22, 14:00
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial eval
Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors.
July 20, 14:00
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambas
In Vivo Car T Infographic from Novotech
July 18, 11:30
Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Economics
With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical Contract Research Organization (CRO) and scientific advisory company, offer
July 17, 14:23
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of
July 17, 10:51
PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala
PCI Pharma Services (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fpci.com%2F&esheet=54289682&newsitemid=20250714606219&lan=en-US&anchor=PCI+Pharma+Services&index=1&md5=d5060a2fa63
July 16, 15:00
Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions
A new Danish study finds no association between aluminum in childhood vaccines and 50 different health conditions, including autism, asthma, and autoimmune diseases. The findings reaffirm the safety o
Dr. Cohen
July 16, 09:55
SBC Medical Appoints Dr. Steven R. Cohen as Medical Strategy Advisor to Accelerate Global Expansion
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announ
HistoSonics Non-Invasive Edison Histotripsy System
July 15, 14:50
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 7 Million Blue Cross Blue Shield Highmark Members
HistoSonics (https://histosonics.com/), the manufacturer of the Edison® Histotripsy System, today announced that Highmark Blue Cross Blue Shield has issued four new positive medical policy decisions f
July 14, 16:29
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54289672&newsitemid=20250714054710&lan=en-US&ancho
July 13, 09:55
iFIT Partners with Samsung Health to Bring Personalized Fitness and Wellness to Millions Across the Globe
iFIT, a global leader in connected fitness and interactive content, today announced a groundbreaking partnership with Samsung Health, one of the world’s most recognized names in technology. This strat
July 11, 17:15
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research
Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3
July 11, 10:50
Newly Elected Directors of Sinovac Hold the First Board Meeting
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprisin
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
July 11, 10:20
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technolo
STAvesta
July 10, 14:40
Rigaku Announces STAvesta, a Thermal Analyzer Tailor-made for Next-generation Material Development
Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched worldwide sales of STAvesta, a thermal analyzer
July 09, 11:35
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella
The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts - early
July 09, 10:45
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company see
July 08, 15:10
CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology
CorFlow Therapeutics AG (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.corflow.com&esheet=54285516&newsitemid=20250707156114&lan=en-US&anchor=CorFlow+Therapeutics+AG&index=1&md5
Novotech Wins Global CRO Award
July 04, 10:00
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost
July 02, 17:08
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro
July 01, 14:13
Galderma Announces Departure of Its Chief Financial Officer
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive o
July 01, 14:10
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (hu
June 29, 14:10
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction ass
Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
June 27, 14:20
Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
Six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have today adopted the first joint ethical principle in the h
June 27, 13:45
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
In a significant showcase for investors, BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its
IFF’s 2024 Do More Good Report Highlights Progress in Sustainability and Innovation
June 27, 11:20
IFF’s 2024 Do More Good Report Highlights Progress in Sustainability and Innovation
IFF (https://www.iff.com/) (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health, and biosciences—has released its 2024 Do More Good Report (https://www.iff.com/sustainabilityre
BARRICURE at Immunodermatology Updates 2025
June 27, 10:20
MEDIPEAU Inc Showcases “BARRICURE” Medical Device Brand for Damaged Skin at Malaysia’s ‘Immunodermatology Updates 2025’ Symposium
On June 23, 2025, the ‘Immunodermatology Updates 2025’ symposium was held in Malaysia. At this event, CHAYA AND LIGHT SDN. BHD., the official Malaysian distribution partner of MEDIPEAU Inc., introduce
June 26, 11:00
Parse Biosciences GigaLab to Support Mount Sinai Researchers in Generating One of the Largest Alzheimer’s and Parkinson’s Single Cell Datasets
Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on understandin
June 25, 16:20
Takeda Announces New Assignments of Directors
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Taked
June 25, 15:00
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients li
June 24, 16:20
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired
25 per page50 per page75 per page100 per page